Journal

Adiponectin in Chronic Kidney Disease

Read time: 1 mins

Published: 8th Dec 2020

Author: Przybyciński J, Dziedziejko V, Puchałowicz K, Domański L, Pawlik A.

Source: International Journal of Molecular Sciences

Availability: Free full text

Ref.: Int J Mol Sci. 2020 Dec 9;21(24):9375.

DOI: 10.3390/ijms21249375

Adiponectin in Chronic Kidney Disease

Adiponectin is the adipokine associated with insulin sensitization, reducing liver gluconeogenesis, and increasing fatty acid oxidation and glucose uptake. Adiponectin is present in the kidneys, mainly in the arterial endothelium and smooth muscle cells, as well as in the capillary endothelium, and might be considered as a marker of many negative factors in chronic kidney disease. The last few years have brought a rising body of evidence that adiponectin is a multipotential protein with anti-inflammatory, metabolic, anti-atherogenic, and reactive oxygen species (ROS) protective actions. Similarly, adiponectin has shown many positive and direct actions in kidney diseases, and among many kidney cells. Data from large cross-sectional and cohort studies showed a positive correlation between serum adiponectin and mortality in chronic kidney disease. This suggests a complex interaction between local adiponectin action, comorbidities, and uremic milieu. In this review we discuss the role of adiponectin in chronic kidney disease.

Read abstract on library site Access full article

A blood draw being performed on the inside of a person's arm; testing for hyperkalaemia

Hyperkalemia

Disease information, latest news, and guidelines

A digital image of two human kidneys, stylised in blue and red

Chronic kidney disease

Expert insights on diagnosis and novel treatments

Digital close up of human kidney glomerulus and the Bowman Capsule

Glomerulonephritis

Unmet needs, latest news, and guideline updates

Featured Learning Zones

patient receiving dialysis, hospital image

Learning Zone

Chronic Kidney Disease Learning Zone

Chronic Kidney Disease (CKD) is a disease that can often lead to a need for haemodialysis and kidney transplantation. New CKD treatments are emerging which focus on delaying CKD disease progression and the need for transplantation.

You may be interested in...

Guideline

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

The joint AAD–NPF guideline provides evidence‑based recommendations for the use of topical therapies and select alternative medicine approaches in psoriasis management. It offers updated guidance on severity assessment measures, treatment selection, and patient‑centred approaches to optimise outcomes in mild‑to‑moderate disease.

Guideline

French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025

These updated French guidelines provide new decision‑making algorithms for systemic treatment of moderate‑to‑severe psoriasis in adults. They incorporate recent evidence, integrate emerging systemic therapies, and offer recommendations for plaque psoriasis, psoriatic arthritis, comorbidities and special situations such as pregnancy.

Guideline

S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations

The EuroGuiDerm‑adapted S3 guideline part 2 provides recommendations for treating psoriasis vulgaris in patients with specific clinical presentations or comorbidities. It addresses management in pregnancy, infection risk, metabolic syndrome, organ‑specific disease, and difficult‑to‑treat areas, offering expert‑driven practical guidance.